Affidea Group Partners with b-rayZ to Enhance Breast Cancer Diagnostics

THE HAGUE, The Netherlands, June 30, 2025 (GLOBE NEWSWIRE) -- Affidea Group, a prominent pan-European provider of community-based healthcare services, has selected b-rayZ, a leader in artificial intelligence (AI) solutions for breast imaging, as its preferred AI partner. This strategic collaboration aims to enhance patient outcomes in breast cancer diagnostics, addressing the prevalent issue of fragmented information across various diagnostic modalities.

Breast cancer remains one of the leading causes of mortality among women globally, necessitating prompt and accurate diagnostic processes. According to the World Health Organization (WHO), early detection significantly increases survival rates, making reliable imaging solutions critical. Affidea's decision to partner with b-rayZ reflects a growing trend in healthcare towards integrating AI to improve clinical precision and efficiency.

Cristina Rossi, CEO and founder of b-rayZ, emphasized the significance of the partnership, stating, "At b-rayZ, we are deeply committed to preserving women’s health. Every woman’s journey through breast cancer diagnosis is unique, and our AI solutions are designed to provide the highest level of diagnostic accuracy and efficiency tailored to each individual’s needs. Being selected by Affidea as their preferred AI partner validates our shared vision of transforming breast cancer diagnostics."

The b-rayZ AI platform is engineered to streamline the diagnostic pathway, ensuring that vital information is readily accessible to healthcare professionals. This is particularly important in breast cancer diagnostics, where timely access to accurate information can lead to life-saving interventions. Dr. Charles Niehaus, Deputy CEO of Affidea, highlighted the broader implications of this collaboration, stating, "This partnership represents a strategic alliance aimed at redefining breast cancer diagnostics. By integrating AI across our network, we are ensuring that women receive the most accurate and timely diagnoses possible."

The initial implementation of b-rayZ’s technology has already shown promise at Affidea’s Centre of Excellence in Breast Cancer located in Zurich, Switzerland, as well as other facilities in Lithuania and Spain. With plans for further expansion across Affidea’s network, the collaboration seeks to enhance the quality of breast imaging services throughout Europe. Dr. Alessandro Roncacci, SVP and Chief Medical Officer at Affidea, noted that AI-powered solutions are revolutionizing the field by augmenting radiologists' expertise and ensuring greater consistency in detection. He stated, "This marks a significant step forward in delivering earlier diagnoses and ultimately ensuring the best possible clinical outcomes for women across Europe."

Affidea Group, founded in 1991, operates over 410 centers across 15 countries, with a commitment to patient safety and quality care. The company has been recognized as the most awarded diagnostic imaging provider in Europe by the European Society of Radiology (ESR), with over 90% of its centers acknowledged on the Eurosafe Wall of Stars. In addition to its partnership with b-rayZ, Affidea has joined as a strategic investor in their Series A extension equity funding round, further strengthening the collaboration's foundation and enabling both organizations to enhance their offerings.

As healthcare continues to evolve with technological advancements, the collaboration between Affidea and b-rayZ illustrates a significant leap towards personalized medicine in breast cancer diagnostics. This partnership is expected to set new standards in patient care, emphasizing the necessity of integrating innovative solutions in healthcare to meet the unique needs of patients. With the global push for improved healthcare outcomes, such strategic alliances are likely to become increasingly vital in the fight against cancer.